School of Pharmacy, The University of Jordan, Amman, Jordan.
School of Medicine, the University of Jordan, Amman, Jordan.
Endocr Metab Immune Disord Drug Targets. 2020;20(9):1552-1557. doi: 10.2174/1871530320666200525012811.
Megalin is a renal proximal tubular protein that reabsorbs vitamin D from glomerular filtrates. Previous studies found significantly higher levels of urinary megalin in chronic microvascular complications of diabetes with associated metabolic derangements. This study aimed at testing the effect of vitamin D supplements on urinary megalin levels in diabetic nephropathy (DN) patients with vitamin D hypovitaminosis.
Sixty-three participants with vitamin D deficiency and diabetic nephropathy (DN) were enrolled in the pre-post study; urinary megalin levels with various clinical parameters and serum levels of vitamin D3 were measured and compared to the baseline at 3- and 6-month intervals.
Interestingly, a supplementation related increase in serum vitamin D3 levels at 3- and 6- month interventions affected a constellation of ameliorations in the DN progression of clinical and metabolic factors. There was a decrease in ACR with a concomitant decrease in urinary megalin and a decrease in blood pressure, fasting plasma glucose (FPG), and low-density lipoprotein - cholesterol (LDL-C) - but an increase in glomerular filtration rate (GFR). Principally, pellet urinary megalin associated positively (p < 0.05) with vitamin D hypovitaminosis and the albumin-to-creatinine ratio (ACR) but negatively (p < 0.05) with Ca2+ and body mass index (BMI).
Vitamin D supplementation could elucidate underlying pathophysiological mechanisms and a prognostic significance of urinary megalin association with DN, obesity/MetS-related dyslipidemia, and hyperglycemia modification. Megalin is a putative sensitive and precise predictive marker and an emerging therapeutic target of renal anomalies.
巨球蛋白是一种肾脏近端小管蛋白,可从肾小球滤过液中重吸收维生素 D。先前的研究发现,患有代谢紊乱相关慢性微血管并发症的糖尿病患者的尿巨球蛋白水平显著升高。本研究旨在检测维生素 D 补充剂对维生素 D 缺乏和糖尿病肾病(DN)患者尿巨球蛋白水平的影响。
63 名维生素 D 缺乏和糖尿病肾病(DN)患者参加了本项前后研究;测量并比较了不同临床参数和血清维生素 D3 水平与基线相比,在 3 个月和 6 个月间隔时的尿巨球蛋白水平。
有趣的是,3 个月和 6 个月干预时血清维生素 D3 水平的补充相关增加影响了 DN 进展的一系列临床和代谢因素的改善。ACR 降低,尿巨球蛋白降低,血压、空腹血糖(FPG)和低密度脂蛋白胆固醇(LDL-C)降低,但肾小球滤过率(GFR)升高。主要是,尿巨球蛋白与维生素 D 缺乏症和白蛋白/肌酐比(ACR)呈正相关(p<0.05),但与 Ca2+和体重指数(BMI)呈负相关(p<0.05)。
维生素 D 补充可能阐明了尿巨球蛋白与 DN、肥胖/代谢综合征相关血脂异常和高血糖改变相关的潜在病理生理机制和预后意义。巨球蛋白是一种有前途的敏感和精确的预测标志物,也是肾脏异常的新兴治疗靶点。